Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent ...

Gilead Sciences has raided Sanofi for its next chief medical officer, luring Dietmar Berger, M.D., Ph.D., away from the ...

Padlock Therapeutics investors accused Bristol Myers of avoiding making milestone payments promised under a 2016 deal.

Gilead may be looking for a deal-broker who can kick-start the company’s growth after the lacklustre launch of its CAR-T therapy, after CEO John Milligan announced he is to step down.

Gilead Sciences has entered a strategic partnership with Terray Therapeutics for the discovery and development of ...

Shares of Assembly Biosciences (NASDAQ:ASMB) traded higher on Thursday after Gilead Sciences (NASDAQ:GILD) agreed to increase ...

Officer," said Gilead CEO Daniel O'Day. Berger will take on responsibility for Gilead's virology, oncology and inflammation portfolio, and will oversee its global development and medical affairs ...

(Reuters) -Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent Merdad Parsey, who is preparing to leave early next year. Berger, ...